Business
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
SAN CARLOS, Calif., December 18, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment.
About this update from Beone Medicines Ltd. Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":28492,"height":5743,"url":"https://media.zenfs.com/en/business-wire.com/308572a805f619da2a4358b438b0a4e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RYVGYXU9jjpeRQCIQoqENQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/308572a805f619da2a4358b438b0a4e3","width":960,"height":194},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/aWY.EF8HjLKnPS2Z_2AffA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/308572a805f619da2a4358b438b0a4e3","width":1200,"height":242}},"lazy":false},{"type":"text","content":"BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer","length":106,"tagName":"p","attribs":{}},{"type":"text","content":"FDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"SAN CARLOS, Calif., December 18, 2025--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment.","length":441,"tagName":"p"},{"type":"text","content":""The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options," said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne.","length":407,"tagName":"p"},{"type":"text","content":"BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tislelizumab).","length":225,"tagName":"p"},{"type":"text","content":"About Hepatocellular Carcinoma","length":30,"tag...